TITLE

Buprenorphine 5,10 and 20 μg/h Transdermal Patch: A Guide to Its Use in Chronic Non-Malignant Pain

AUTHOR(S)
Plosker, Greg L.; Lyseng-Williamson, Katherine A.
PUB. DATE
April 2012
SOURCE
CNS Drugs;2012, Vol. 26 Issue 4, p367
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Buprenorphine lower-dose (5, 10 and 20 μg/h) transdermal patches, which are administered once every 7 days, are indicated in the management of chronic non-malignant pain. This review focuses on the labelling of this for- mulation (BuTrans®) in the EU. The analgesic efficacy of transdermal bu- prenorphine in patients with osteoarthritis of the hip and/or knee has been demonstrated to be equivalent to sublingual buprenorphine, noninferior to prolonged-release tramadol and generally superior to a matching transder- mal placebo patch. When used together with regularly scheduled oral paracetamol (acetaminophen), transdermal buprenorphine was noninferior to codeine plus paracetamol. Transdermal buprenorphine has also shown analgesic efficacy in patients with chronic non-malignant pain of various causes.
ACCESSION #
75372359

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics